316 results on '"ter Maaten, Jozine M."'
Search Results
2. The utility of urine sodium–guided diuresis during acute decompensated heart failure
3. Urinary Marker Profiles in Heart Failure with Reduced Versus Preserved Ejection Fraction
4. Natriuresis-guided diuretic therapy in acute heart failure: a pragmatic randomized trial
5. Titration of Medications After Acute Heart Failure Is Safe, Tolerated, and Effective Regardless of Risk
6. Characteristics, treatment, and outcomes of early vs. late enrollees of the STRONG-HF trial
7. A patient with recurrent syncope—it does matter how slow and long you go
8. Abstract 14576: Circulating Bone Morphogenetic Protein 10 as a Prognostic Biomarker in Heart Failure: A BIOSTAT-CHF Study
9. Pathophysiologic Processes and Novel Biomarkers Associated With Congestion in Heart Failure
10. Punto de corte óptimo del antígeno carbohidrato 125 para la identificación de pacientes con bajo riesgo tras un ingreso por insuficiencia cardiaca aguda
11. Renal Compression in Heart Failure: The Renal Tamponade Hypothesis
12. Achieved dose and treatment discontinuation of candesartan in men and women with chronic heart failure: data from CHARM.
13. Prediction of new‐onset heart failure in patients with type 2 diabetes derived from ALTITUDE and CANVAS.
14. Decongestion With Acetazolamide in Acute Decompensated Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction: A Prespecified Analysis From the ADVOR Trial
15. Corticosteroid burst therapy in patients with acute heart failure: Design of the CORTAHF pilot study.
16. Renal function and natriuresis‐guided diuretic therapy – a pre‐specified analysis from the PUSH‐AHF trial.
17. Dietary sodium and fluid intake in heart failure. A clinical consensus statement of the Heart Failure Association of the ESC.
18. Clinical Role of CA125 in Worsening Heart Failure: A BIOSTAT-CHF Study Subanalysis
19. Letter by Beldhuis et al Regarding Article, “Potential Role of Natriuretic Response to Furosemide Stress Test During Acute Heart Failure”
20. A combined clinical and biomarker approach to predict diuretic response in acute heart failure
21. Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment
22. Trajectories of Changes in Renal Function in Patients with Acute Heart Failure
23. Response to Cardiac Resynchronization Therapy Across Chronic Kidney Disease Stages
24. Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction
25. The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure
26. The role of the kidney in acute and chronic heart failure
27. Very Early Diuretic Response After Admission for Acute Heart Failure
28. Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure
29. Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure
30. Subcutaneous Furosemide in Heart Failure: Pharmacokinetic Characteristics of a Newly Buffered Solution
31. Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure: Results From BIOSTAT-CHF
32. Serum Potassium Levels and Outcome in Acute Heart Failure (Data from the PROTECT and COACH Trials)
33. Early changes in renal function during rapid up‐titration of guideline‐directed medical therapy following an admission for acute heart failure.
34. Correction to: The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure
35. Perirenal Adipose Tissue Is Associated With Renal Dysfunction and Abnormal Hemodynamics in Patients With HFpEF
36. The risk of death associated with proteinuria in heart failure is restricted to patients with an elevated blood urea nitrogen to creatinine ratio
37. MicroRNAs relate to early worsening of renal function in patients with acute heart failure
38. Proenkephalin, an Opioid System Surrogate, as a Novel Comprehensive Renal Marker in Heart Failure
39. Mineralocorticoid receptor antagonist initiation during admission is associated with improved outcomes irrespective of ejection fraction in patients with acute heart failure.
40. Sodium and potassium changes during decongestion with acetazolamide – A pre‐specified analysis from the ADVOR trial.
41. Sex‐specific analysis of the rapid up‐titration of guideline‐directed medical therapies after a hospitalization for acute heart failure: Insights from the STRONG‐HF trial.
42. Pain score, desire for pain treatment and effect on pain satisfaction in the emergency department: a prospective, observational study
43. Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction
44. Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT‐CHF
45. Impact of mitral regurgitation in patients with acute heart failure: insights from the RELAX‐AHF‐2 trial.
46. Renin–Angiotensin System Inhibition, Worsening Renal Function, and Outcome in Heart Failure Patients With Reduced and Preserved Ejection Fraction: A Meta-Analysis of Published Study Data
47. Associations of Body Mass Index With Laboratory and Biomarkers in Patients With Acute Heart Failure
48. Decongestion with Acetazolamide in Acute Decompensated Heart Failure across the Spectrum of Left Ventricular Ejection Fraction: a Pre-specified Analysis from the ADVOR trial.
49. Characteristics and clinical outcomes of patients with acute heart failure with a supranormal left ventricular ejection fraction.
50. Creatinine excretion rate, a marker of muscle mass, is related to clinical outcome in patients with chronic systolic heart failure
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.